Stock Rating Upgrade
During the last several trading days the Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) rose significantly from D to B reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock closed at $296.91 on 2/28/25 after a large increase of 2.3%. Moreover, above average trading volume at 146% of normal accompanied the advance. The stock has risen 1.4% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
VERISK ANALYTICS INC has a current Value Trend Rating of B (Positive). This VT Rating rose significantly in recent days from D previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. VERISK ANALYTICS INC has a neutral Power Rating of 52 but a good Appreciation Score of 80, and the Positive Value Trend Rating results.
Be the first to comment